Bringing hope through science

Oncopeptalks – first order in Italy and Q4 report

March 13, 2025

In the latest episode of Oncopeptalks, David and Sofia discuss the recent news of a first Pepaxti order in Italy and some of the questions following the Q4 report.

Read more

Oncopeptides receives first order of Pepaxti in Italy

March 11, 2025

Read more

Regarding recent media attention

February 4, 2025

On Friday, January 31, the Danish Medicines Council, an independent council that produces recommendations and guidelines on medicines for the country's five regions, published a decision to recommend a restriction on the use of the drug lenalidomide.

Read more

Strong real-world efficacy and safety data with Pepaxti published in the European Journal of Haematology

February 25, 2025

Oncopeptides AB today announces that a new real-world study on melflufen (melphalan flufenamide, branded in Europe as Pepaxti) plus dexamethasone in patients with relapsed, refractory multiple myeloma (RRMM) has been published in the peer-reviewed journal European Journal of Haematology.

Read more

Oncopeptides invited to present at ASH in December

November 20, 2024

Oncopeptides today announces that an evaluation of the activity of two peptide drug conjugates (PDCs) developed by Oncopeptides in relapsed or refractory Acute Myeloid Leukemia has been accepted as a poster and will be presented at the 66th annual American Society of Hematology (ASH) Meeting and Exposition. The conference takes place in San Diego, California between December 7-10.

Read more

First patient enters real-world data study in Germany

July 22, 2024

Oncopeptides recently announced entry of the first patient in a new study evaluating the real-world effectiveness and safety of Pepaxti in German patients.

Read more